| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Oxymatrine (also known as Matrine N-oxide) is a naturally occuring quinolizidine alkaloid isolated from the root of Sophora flavescens, which is used for the treatment of viral hepatitis, cancer, viral myocarditis, gastrointestinal hemorrhage and skin diseases such as colpitis, psoriasis and eczema etc. Oxymatrine protects mice from fulminant hepatitis induced by GalN/LPS and may block hepatocyte apoptosis and subsequent necrosis through downregulating the production of serum tumor necrosis factor alpha and the expression of Fas and Fas ligand in liver tissue. Oxymatrine also shows anti-hepatitis B virus effect in vivo by reducing the contents of HBsAg and HBcAg in transgenic mice liver.
| ln Vitro |
An alkaloid called oxymatrine, which is taken from the roots of Sophora flavescens, has been demonstrated to have anti-inflammatory, anti-fibrotic, anti-tumor, and heart-protective properties. Potential signaling pathways for oxymatrine include the following: delta-opioid receptor-Bcl-2, CD40, nuclear factor erythroid-2-related factor 2/heme oxygenase-1 signaling pathway, dimethyl arginine dimethylaminohydrolase/asymmetric dimethylarginine metabolic pathway, Janus kinase/signal transducer and activator of transcription, toll-like receptor 9/TRAF6, delta-opioid receptor-activated B cell nuclear factor kappa light chain enhancer, and delta-opioid receptor-Bcl-2 [1]. The growth of PC-3 and DU145 cell lines was dramatically suppressed by oxymatrine in a time- and dose-dependent manner. On the other hand, oxymatrine therapy did not suppress the proliferation of PNT1B healthy human prostate cells [2].
|
||
|---|---|---|---|
| ln Vivo |
The dose-dependent reduction in the volume and weight of the mouse tumors was substantial. Oxymatrine induces apoptosis in vivo, which slows the proliferation of prostate cancer cells [2]. The formation and deposition of collagen in the liver tissue of experimental rats is significantly reduced by oxymatrine. When CCl4 induces liver fibrosis in SD rats, oxymatrine can regulate the TGFβ-Smad pathway's fibrosis signal transduction by upregulating the expression of Smad 7 and downregulating the expression of Smad 3 and CBP [3].
|
||
| Animal Protocol |
|
||
| References |
[1]. Lu ML, et al. Potential Signaling Pathways Involved in the Clinical Application of Oxymatrine. Phytother Res. 2016 Jul;30(7):1104-12.
[2]. Wu C, et al. Oxymatrine inhibits the proliferation of prostate cancer cells in vitro and in vivo. Mol Med Rep. 2015 Jun;11(6):4129-34. [3]. Wu XL, et al. Effect of Oxymatrine on the TGFbeta-Smad signaling pathway in rats with CCl4-induced hepatic fibrosis. World J Gastroenterol. 2008 Apr 7;14(13):2100-5. [4]. Ding Y, et al. Oxymatrine Inhibits Bocavirus MVC Replication, Reduces Viral Gene Expression and Decreases Apoptosis Induced by Viral Infection. Virol Sin. 2019 Feb;34(1):78-87 |
| Molecular Formula |
C15H24N2O2
|
|
|---|---|---|
| Molecular Weight |
264.36
|
|
| CAS # |
16837-52-8
|
|
| Related CAS # |
|
|
| SMILES |
[O-][N+]12C([H])([H])C([H])([H])C([H])([H])C3([H])C([H])([H])N4C(C([H])([H])C([H])([H])C([H])([H])C4([H])C([H])(C([H])([H])C([H])([H])C1([H])[H])C23[H])=O
|
|
| InChi Key |
XVPBINOPNYFXID-VNSSVHEPSA-N
|
|
| InChi Code |
InChI=1S/C15H24N2O2/c18-14-7-1-6-13-12-5-3-9-17(19)8-2-4-11(15(12)17)10-16(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15+,17+/m0/s1
|
|
| Chemical Name |
(4R,41R,7aS,13aR,13bR)-10-oxododecahydro-1H,5H-dipyrido[2,1-f:3,2,1-ij][1,6]naphthyridine 4(41H)-oxide
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (378.27 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7827 mL | 18.9136 mL | 37.8272 mL | |
| 5 mM | 0.7565 mL | 3.7827 mL | 7.5654 mL | |
| 10 mM | 0.3783 mL | 1.8914 mL | 3.7827 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA